Elite Pharmaceuticals receives FDA approval on its NDA for ADHD treatment

seekingalpha
18 Nov 2024
  • Elite Pharmaceuticals (OTCQB:ELTP) received approval from the US Food and Drug Administration for an Abbreviated New Drug Application for a generic version of Vyvanse with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules.
  • The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder.
  • Stock is up 5% premarket.
  • Source: Press Release

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10